RCT: Terminal complement inhibitor Ravulizumab in generalized myasthenia gravis.
9 May, 2022 | 01:27h | UTCTerminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis – NEJM Evidence
Commentary on Twitter
In this RCT, Ravulizumab provided rapid and efficacious treatment of adult patients with anti-AChR antibody-positive generalized myasthenia gravis (gMG), as determined by both patient- and clinician-rated outcomes, with few adverse events. https://t.co/9mlCOULiJR#NeuroTwitter pic.twitter.com/ZljrTs282f
— NEJM Evidence (@NEJMEvidence) May 3, 2022